Direct oral anticoagulants in patients with thrombophilia : challenges in diagnostic evaluation and treatment by unknown
dose response, fewer drug and food interactions, 
and no need for laboratory monitoring of the in-
ternational normalized ratio (INR) or other coag-
ulation tests [3]. Based on randomized controlled 
trials on DOACs in DVT or PE patients, the new-
er anticoagulants have been convincingly demon-
strated to be at least as effective as the convention-
al treatment with low-molecular-weight heparins 
(LMWH) followed by VKAs in preventing recur-
rent VTE [4, 5].
In a pooled analysis of the 6 phase 3 trials, recur-
rent VTE and VTE-related deaths occurred in 2.0% 
of patients receiving DOACs compared with 2.2% 
of those given VKAs (relative risk [RR] 0.90, 95% 
Direct oral anticoagulants (DOACs) or non-
vitamin K  oral anticoagulants (NOACs) are ap-
proved for stroke prevention in patients with 
non-valvular atrial fibrillation (AF) and therapy 
of venous thromboembolism (VTE) encompassing 
deep vein thrombosis (DVT) and pulmonary em-
bolism (PE) [1–3]. The DOACs currently available 
in Europe include 3 direct factor Xa inhibitors, ri-
varoxaban, apixaban and edoxaban, and 1  direct 
thrombin inhibitor, dabigatran. In  Poland, rivar-
oxaban, apixaban and dabigatran are currently be-
ing used (Table 1).
DOACs offer a number of advantages over vi-
tamin K antagonists (VKAs) such as a predictable 
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Abstract
Direct oral anticoagulants (DOACs) or non-vitamin K oral anticoagulants (NOACs) are increasingly used in the 
prevention of recurrent venous thromboembolism (VTE), including that associated with thrombophilia. The effi-
cacy of DOACs in thrombophilic patients, especially those with severe trombophilia or triple positive antiphos-
pholipid syndrome (APS) with arterial thromboembolic events, remains controversial. Most case reports and case 
series indicate that DOACs are an attractive therapeutic option in the vast majority of these patients at high risk of 
recurrent VTE with more concerns raised in high-risk APS patients and these deficient in protein S (PS). Adherence 
to DOACs is of paramount importance in these patients. In this review we presented available data on the manage-
ment of patients with thrombophilia using rivaroxaban, dabigatran or apixaban at standard doses. Moreover, we 
also demonstrated the overall effects of DOACs on coagulation tests, particularly those determined during throm-
bophilia screening such as lupus anticoagulant, antithrombin, protein C, PS, activated protein C  ratio. Despite 
the paucity of data from randomized studies, the current evidence supports the use of DOACs in thrombophilia, 
especially those who prefer such treatment or have unstable anticoagulation with vitamin K antagonists or unac-
ceptable adverse events while using these drugs (Adv Clin Exp Med 2016, 25, 6, 1321–1330).
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confidence interval [CI]: 0.77–1.06). For acute VTE 
treatment, the DOACs are non-inferior to well-
managed VKA therapy [5]. Importantly, there was 
overall a 40% reduction in the risk of major bleed-
ing in patients receiving DOACs with lower risks of 
intracranial bleeding (63% relative reduction), fa-
tal bleeding (64% relative reduction), and clinically 
relevant non-major bleeding (27% relative reduc-
tion) [4]. With similar efficacy, better safety and the 
convenience of fixed dosing, guidelines now recom-
mend the DOACs over VKAs for VTE treatment in 
patients without active cancer [5].  Appropriate an-
ticoagulation in VTE patients reduces the risk of 
recurrent VTE, including life-threatening PE, and 
postthrombotic syndrome [6, 7].
Inherited Thrombophilia
Natural anticoagulant deficiencies (protein C, 
PC, or protein S, PS, or antithrombin, AT), ho-
mozygous factor V  Leiden (FVL) and prothrom-
bin G20210A, or combined defects, result in a se-
vere thrombophilia phenotype, which occurs in 
approximately 4% of patients with idiopathic 
VTE [8]. Less commonly inherited thrombophilia 
is observed in patients with myocardial infarction 
or ischemic stroke [9].
In  everyday practice VKAs are preferred in 
the therapy of VTE associated with thrombo-
philia. The  prevalence of known thrombophil-
ia in the VTE trials with DOACs ranged from 2 
to 18% [10]. To our knowledge, only the data for 
thrombophilic patients with acute VTE participat-
ing in the RECOVER I and RECOVER II studies 
that assessed the efficacy and safety of dabigatran 
(150 mg bid) administered for 6–36 months were 
published as an abstract [11]. Thrombophilia was 
determined in 34% of the VTE patients yielding 
positive results in 24% of the cases, with no dif-
ferences between dabigatran- and warfarin-treated 
individuals with FVL, prothrombin 20210A  vari-
ant, deficiencies in AT, PC or PS as well as lupus 
anticoagulant (LA) or anticardiolipin antibodies. 
No differences in the efficacy or safety of dabiga-
tran use depending on the thrombophilic factors 
were observed; however, dabigatran was used in as 
few as 11 AT deficient patients and 25 with PC or 
PS deficiency. The  combined defects or homozy-
gous mutations were not reported [12]. Below we 
present patients with severe inherited thrombo-
philia who were treated with DOACs and were re-
ported in the literature.
Antithrombin Deficiency
Inherited AT deficiency is an autosomal 
dominant disorder with prevalence in the gen-
eral population estimated between 1  :  500 and 
1 : 5000 [13, 14]. This abnormality is diagnosed in 
0.5–4.9% of patients after the first incident of VTE. 
In Poland, several AT deficient patients with VTE 
have been reported since 2011  [15–20]. There is 
Table 1. Characteristics of dabigatran, rivaroxaban and apixaban (reprinted with permission from Undas et al. [12], modified)
Variable Warfarin Dabigatran etexilatea Rivaroxaban Apixaban
Mode of action ↓ synthesis vitamin 
K-dependent coag-
ulation factors
direct selective and 
reversible thrombin 
inhibitor
direct selective and 
reversible activated fac-
tor X inhibitor
direct selective and 
reversible activated 
factor X inhibitor
Time to peak plasma 
concentration
90 min (peak action 
after 4–5 d)
0.5–2 h 2–4 h 1–4 h





no yes yes yes








Route of elimination various 80% renal 66% renal  
(33% unchanged)
25% renal
Protein binding 99% 35% 90% 90%
Basic daily dose in AF ~5 mg (1–18 mg)
target INR, 2–3
2 × 150 mg 1 × 20 mg 2 × 5 mg
Reduced daily dose not applicable 2 × 110 mg 1 × 15 mg 2 × 2.5 mg
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a 50-fold increased risk of VTE in AT deficient in-
dividuals [21, 14]
Experience with DOACs in AT deficiency 
is very limited. Cases of a  49-year-old male with 
AT deficiency and Crohn disease who was suc-
cessfully treated with apixaban for 9  months and 
a  12-year-old girl with heparin-resistant severe 
thrombosis due to AT deficiency (homozygous 
AT Budapest  III) treated with rivaroxaban have 
been published recently [22, 23]. DOACs that act 
directly without the participation of AT may rep-
resent a  particularly attractive anticoagulant al-
ternative to LMWH in AT deficient patients with 
a marked resistance to these agents [23]. Taken to-
gether, most AT deficient patients can be success-
fully treated with DOACs.
Protein C Deficiency
The  prevalence of PC deficiency is estimated 
at 0.2–0.3% in the European population and 3% of 
patients after the first VTE [24]. We characterized 
genetically the first two Polish patients with PC de-
ficiency [25, 26]. There is about a 10-fold increased 
risk of VTE in PC deficient subjects [14, 21].
Little is known about the efficacy of DOACs 
in PC deficient patients. Protein C deficiency com-
plicated with warfarin-induced skin necrosis was 
successfully treated with dabigatran at standard 
doses [27]. In an 18-year-old woman with two PC 
mutations and the PC level of 3% warfarin therapy 
was changed to rivaroxaban with the subsequent 
increase of PC levels to 12–18%, but after miss-
ing two doses of rivaroxaban she developed upper 
limb DVT [10].
Protein S Deficiency
The  prevalence of PS deficiency is estimated 
at  0.5% in Europe and at 2–12% among patients 
after the first incident of VTE [24, 28]. The Polish 
patients with this thrombophilia genetically char-
acterized have been described recently [29–31, 32]. 
There is a 10-fold increased risk of VTE in PS de-
ficient subjects [14, 21].
We  showed recurrent VTE in two type  1 PS 
deficient patients with low free PS, below 20% 
of the reference range, who were treated with riva-
roxaban, suggesting that this thrombophilia could 
be a  risk factor for recurrent VTE on rivaroxa-
ban [33]. In a 6-year-old child with severe homo-
zygous PS deficiency rivaroxaban 40 mg/d was re-
ported to be effective, indicating that higher doses 
of rivaroxaban are needed at low PS levels to pro-




The  most common thrombophilia in Cauca-
sians is FVL mutation that occurs in 5% of Cau-
casians and 3–7 times more commonly in patients 
with VTE. There is a 80-fold increased risk of VTE 
in homozygous FVL carriers  [14, 21]. Prothrom-
bin G20210A  polymorphism, the second most 
common heritable thrombophilia, occurs in 3% 
of Europeans and is associated with similar VTE 
risk [14].
To our knowledge, the only report on the use 
of DOACs in FVL has described left ovarian and 
renal vein thromboses in a 30-year-old woman ho-
mozygous for FVL, taking combined oral contra-
ceptives, which were successfully treated with riva-
roxaban 20 mg/d [34]. Recently, acute myocardial 
infarction in a 65-year-old man receiving rivarox-
aban following idiopathic PE associated with het-
erozygous prothrombin 20210A  mutation has 
been reported [35]. Most experts consider DOACs 
as a safe and effective option for patients with het-
erozygous variants of these polymorphisms and 
likely for the majority of homozygous patients.
Antiphospholipid Syndrome
Antiphospholipid syndrome (APS) is an au-
toimmune acquired disease associated with ve-
nous or arterial thrombosis and recurrent miscar-
riages  [36–38]. The diagnosis of APS is based on 
the clinical presentation and 2 positive measure-
ments of IgG or IgM antibodies against cardiolipin 
(aCL), β2 glycoprotein I  (aβ2GPI), or LA. Young 
patients with VTE or ischemic stroke of unknown 
cause should be tested for APS  [39]. The  stan-
dard treatment for patients diagnosed with APS is 
bridging anticoagulation with heparins followed 
by VKA [36].
There have been a few case reports suggesting 
that DOACs, compared with VKAs, are less bene-
ficial in patients with triple-positive APS, especial-
ly associated with a  stroke, who received dabiga-
tran and rivaroxaban [3, 4]. Despite these reports, 
some experts have recommended NOACs as an 
alternative to VKAs in the prevention of VTE in 
APS  [11]. In  2015 we published a  case series in-
volving 12 patients with APS treated with rivarox-
aban with 2 recurrent DVT episodes [40]. Jolland 
et  al.  [22] and Delgado et  al.  [41] demonstrat-
ed single cases of patients with APS receiving ri-
varoxaban who experienced a thrombosis relapse. 
 Signorelli et al. [42] have presented 8 patients with 
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APS treated with rivaroxaban who experienced 
thrombosis recurrence, including 5  patients with 
triple positivity and 2 subjects with previous arte-
rial thrombosis. On the other hand, several reports 
indicated good efficacy of DOACs in APS even 
with no or only one thrombotic relapse during fol-
low-up [43, 44].
Sciascia et  al.  [10] summarized observational 
studies regarding the use of DOACs in APS pub-
lished till the end of 2015 (n = 87) and showed rela-
tively good clinical outcomes in patients with APS 
on DOACs during follow-up up to 29  months. 
 Betancur et  al.  [45] reported cases of fully suc-
cessful prevention of VTE recurrence in 7 patients 
treated with rivaroxaban and a  single individual 
on apixaban.
The recurrence rate of thrombosis on DOACs 
observed in available studies is similar to that re-
ported by Cervera et  al.  [46], who demonstrated 
25% recurrence of thrombosis within the 5  years 
period in patients with APS mostly treated with 
anticoagulants. Many experts consider DOACs as 
a valuable therapeutic option in APS patients who 
initiate anticoagulant therapy or prefer such agents 
over VKAs [33]. Other experts are cautious and re-
peat that VKAs remain to be the mainstay treat-
ment for thrombotic APS, unless they refuse to un-
dergo such inconvenient treatment or suffer from 
adverse events [42].
An  open-label, randomized, controlled tri-
al –  rivaroxaban in antiphospholipid syndrome 
(RAPS) study, performed on thrombotic APS pa-
tients allocated to warfarin or rivaroxaban 20 mg 
daily, was published in September 2016  [47]. 
The  primary endpoint, the percentage change in 
endogenous thrombin potential (ETP) from ran-
domization to day 42, was higher in the rivarox-
aban group together with markedly lower peak 
thrombin generation, the most sensitive marker of 
thrombin formation. No VTE episodes or serious 
bleeding were reported, leading to the conclusion 
that rivaroxaban “could be an effective and safe al-
ternative” in thrombotic APS  [47]. Although the 
size of the study groups was limited and the ob-
servation period short, the RAPS study provided 
valuable confirmation that the impact of rivaroxa-
ban on blood coagulation is comparable to warfa-
rin with a target INR of 2.5 in patients with vari-
ous forms of APS.
Own Recent Experience with 
DOACs in Thrombophilia
Recently, we have analyzed 33 adult patients 
with severe thrombophilia aged 19–64 years, who 
had been switched from warfarin or acenocouma-
rol to DOACs [A. Undas, unpublished data]. This 
group included 5 (15%) patients deficient in AT, 
3  (9%) deficient in PC, 4 (12%) deficient in PS, 
1 (3%) homozygous FVL mutation carrier, 3 (9%) 
carriers of homozygous PT G20210A mutation and 
most with combined defects. As few as 3 cases of 
recurrent VTE on DOACs were recorded during 
the follow-up up to 32  months with no fatalities 
[A. Undas, unpublished data]. In our experience, 
PS deficiency appears to be related to the increased 
risk of VTE recurrence, which was observed in 2 of 
the 3 patients who experienced recurrent VTE on 
DOACs. It has been suggested, however, that var-
ious genetically determined thrombophilias could 
affect differently the effect of DOACs [43].
Our recent analysis of 56 consecutive pa-
tients with APS aged 23 to 64 years, including 16 
(28.6%) with triple positive APS, who were treated 
with DOACs supported the concept of satisfacto-
ry efficacy and safety of DOACs, mainly rivaroxa-
ban, in this thrombophilia. During follow-up up to 
43 months, 6 (2.98% per year) patients, including 
4 subjects with triple positive APS, experienced re-
current nonfatal thromboembolic events, includ-
ing 1  myocardial infarction and in 2 cases non-
adherence was observed before the  recurrences 
[A. Undas, unpublished data].
Effect of DOACs on Routine 
Coagulation Tests
The impact of DOACs on the laboratory assays 
depends on the type of the drug, the drug concen-
trations, the assay, reagents and instruments used 
to test the sample [48]. Assays based on thrombin 
are more affected by direct thrombin inhibitors, 
whereas direct FXa inhibitors influenced much 
more FXa-based methods. The  blood levels con-
nected with DOACs vary from a few ng/mL prior 
to drug administration (“trough”), to several hun-
dred ng/mL, if the sample is taken 2–4 h after the 
drug’s intake (“peak”) (Table  2). The  first Polish 
experience with determining dabigatran and riva-
roxaban in the circulating blood was published in 
2014 [49–51]. Table 3 shows the effects of DOACs 
on coagulation assays.
The  presence of rivaroxaban in blood results 
in the prolongation of prothrombin time (PT) in 
a  manner dependent on the concentration of the 
drug, while apixaban has little effect on the PT [52]. 
Rivaroxaban also alters thromboelastographic pa-
rameters  [53]. For rivaroxaban, the concentra-
tion of the drug required to double the clotting 
time (CT) may range from 498 to 591 ng/mL us-
ing Quick-type PT assays in comparison to at least 
1300 ng/mL when tested using Owren-type PT as-
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says  [54]. Apixaban concentrations that ranged 
from 480 to  >  1000  ng/mL led to double the PT 
with the 10 different reagents [55]. It has been ob-
served that the TriniCLOT Excel S  of the PT re-
agents show a dose-dependent response to apixa-
ban across the 0–500 ng/mL range [56].
Increased dabigatran concentrations pro-
longed PT, but the correlation is poor  [57]. 
The  Owren-type PT may be normal in up to 
about ¾ samples with dabigatran of 40  ng/ml or 
above [58]. The PT is not recommended to quan-
tify or even detect dabigatran [59].
Activated partial thromboplastin time (APTT) 
could be useful to determine the anticoagulant 
activity of dabigatran. The  presence of dabiga-
tran in plasma results in the prolongation of the 
APTT in a  concentration- and a  reagent-depen-
dent manner  [60, 61]. Samples containing dabi-
gatran in the amount of 120  ng/mL tested using 
different APTT reagents may give results from 26 
to 92  s  [62]. The correlation between dabigatran 
and the APTT is curvilinear. Linear dose response 
is followed by flattening at about 300 ng/mL [62]. 
The  percentage of normal APTT samples with 
dabigatran concentrations of 40–160  ng/mL 
may reach 26% [58]. The APTT was always pro-
longed when dabigatran concentrations exceeded 
160  ng/mL  [58]. Dabigatran may induce hyper-
coagulable effects by inhibiting thrombomodu-
lin-mediated activation of protein C, which may 
be the cause of normal APTT in individuals with 
high dabigatran concentrations [58].
The  APTT demonstrates a  concentration-de-
pendent prolongation in a nonlinear manner in re-
sponse to direct FXa inhibitors in samples, although 
to a  lesser extent than to dabigatran  [48,  63–65]. 
APTT reagents are much more sensitive to riva-
roxaban and edoxaban than to apixaban  [52]. 
Clotting time of apixaban enriched (100  ng/mL) 
samples was prolonged only 1.1  times compared 
with the control, when measured using 10 differ-
ent APTT reagents [62]. Double CT was obtained 
at rivaroxaban concentrations and ranged from 
330 to 637 ng/mL depending on the reagent [56]. 
The reasons for a much weaker PT and APTT re-
sponse to apixaban compared to rivaroxaban are 
not known  [56], and the phospholipid composi-
tion of the reagents may contribute to this obser-
vation [66].
Thrombin time (TT) is very sensitive to dab-
igatran, and low concentrations of 25  ng/mL 
may render the tested plasma samples unclotta-
ble  [60,  65]. A  normal standard TT can exclude 
the presence of dabigatran in a sample [67]. Dabi-
gatran can be quantified using a chromogenic eca-
rin assay, ecarin clotting time or a  modified (di-
lute) TT, where excessive sensitivity is overcome 
by lower concentrations of heparin or sample di-
lution [60, 68]. Since FXa is not involved in fibrin-
ogen conversion into fibrin, the TT is not affected 
by direct FXa inhibitors [48, 64].
Effect of DOACs on Results 
of Thrombophilia Testing
Lupus Anticoagulant
Lupus Anticoagulant (LA) is detected using as-
says based on APTT or Russel’s viper venom time 
(RVVT) containing reagents with low (screening 
reagents) and high (confirmation reagents) phos-
pholipid concentrations. LA  prolongs clotting 
time using screening reagents much more than 
when using confirmation reagents. Both APTT- 
and RVVT-based assay are affected by DOACs. 
It was shown that dabigatran prolongs the RVVT 
in an almost linear manner, although the correla-
tion was not potent [58]. The RVVT is sensitive to 
low concentrations of dabigatran. Dabigatran con-
centrations below 40 ng/mL prolong the RVVT in 
72% of plasma samples [58].
Table 2. Concentrations of direct oral anticoagulants based on [57, 62, 76, 77, 78]





























* values in ng/mL for peak and trough are expressed as 5th – 95th percentile ranges (dose/bid – twice daily, od – once daily).
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Rivaroxaban prolongs much more the RV-
VT using reagents with small phospholipid con-
tent compared with apixaban, while there is no 
difference in the RVVT if reagents with high phos-
pholipid content are used. Thus, a  false positive 
LA may be obtained for rivaroxaban at 100 ng/mL 
and apixaban at 600  ng/mL  [66]. We  confirmed 
that to reliably evaluate LA  in VTE patients on 
rivaroxaban, blood should be taken at least 24  h 
 after the last drug administration [69]. It has been 
recommended that the LA  testing should be per-
formed 2–3 days after the last dose of DOACs [71].
Activated Protein C 
Resistance (APCR)
The  ratio below about 2.0 of APTT or RV-
VT with and without added exogenous activated 
protein C  (APC) indicates FVL mutation. Assays 
based on APTT or prothrombinase are affect-
ed by dabigatran at a  concentration of 50  ng/mL 
and more  [72]. Our data indicates that rivaroxa-
ban, at least in the therapeutic range of concen-
trations, does not affect APC-R testing using the 
Table 3. Effects of direct oral anticoagulants on coagulation assays
Test Dabigatran Rivaroxaban Apixaban Edoxaban
PT ↑ ↑↑↑ ↑ ↑↑↑
APTT ↑↑↑ ↑↑ ↑ ↑↑
Thrombin time ↑↑↑↑↑ – – –
Reptilase time – – – –
Fibrinogen











  based on FXa inhibition









RVVT ↑ ↑↑↑ ↑↑ ↑↑
Protein C
  clotting assay










  clotting assay 









Activated protein C resistance (ratio)
  based on APTT
  based on RVVT







Anti-FXa – ↑↑↑↑ ↑↑↑↑ ↑↑↑↑
Ecarin clotting time ↑↑ – – –
Intrinsic coagulation factors (VIII, IX, XI, XII)
  based on APTT







Extrinsic coagulation factors (II, V, VII, X)
  based on PT ↓ ↓↓ ↓↓ ↓↓
D-Dimer – – – –
LA (ratio)
 based on APTT





APTT – activated partial thromboplastin time; FIIa – thrombin; FXa – active factor X; PT – prothrombin time; RVVT 
– Russel’s viper venom time (in parentheses – a possible effect of DOACs).
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ProC Ac R RVVT-based assay [70]. This test could 
be recommended if the time from the last dose of 
DOACs is uncertain or unknown. The influence of 
rivaroxaban on an APTT-based assay results in an 
increased APCR ratio. Assays based on prothrom-
binase activation exhibit less sensitivity to rivar-
oxaban and a smaller increase in the APCR ratio 
when concentrations of rivaroxaban increase [54]. 
Genetic testing is the reliable method to confirm 
FVL in patients on DOACs.
Antithrombin
Dabigatran alters thrombin-based chromo-
genic assays leading to overestimated results of AT 
levels, whereas FXa-based assays are unaffected by 
this drug [73]. Estimations of the increase in AT ac-
tivity yield falsely elevated results, i.e., by 12% per 
200 ng/mL of dabigatran [72]. A factitious increase 
in AT activity at 250  ng/mL dabigatran ranged 
from 15 to 21% depending on the reagent [61]. On 
the other hand, direct FXa inhibitors influence sig-
nificantly the FXa-based assays, and, for example, 
rivaroxaban at 290  ng/mL can cause an overesti-
mation of AT activity up to 44% [61].
Protein C
Dabigatran affects the clot-based assays lead-
ing to overestimated PC levels. The  most com-
monly used assay for PC deficiency screening is 
not influenced by DOACs. The  same holds true 
for antigen assays to determine PC [73].
Protein S
Results of PS testing in the presence of dabiga-
tran with any of the clot-based assays (APTT, PT, 
RVVT or FXa) can be falsely increased, while PS 
antigen assays are unaffected [73]. The PS activity 
assays are also influenced by rivaroxaban in a re-
agent-dependent manner. Mean activity of sam-
ples spiked with rivaroxaban of 200  ng/mL was 
174% using the PT-based method, while for RV-
VT- and APTT-based assays mean activities were 
119 and 99%, respectively [74].
Summary
Little is known about the efficacy and safety of 
DOACs in real-life patients diagnosed with severe 
inherited thrombophilia and APS. For this reason, 
the unlimited use of DOACs in patients with such 
thrombophilia is now controversial for many cli-
nicians. On the other hand, given the lack of an-
ticoagulation clinics in Poland, the burden of life-
long anticoagulant treatment with VKAs is large 
and this situation encourages numerous patients 
to seek a transition to DOACs, even if the month-
ly cost of such therapy is considerable. Moreover, 
manufacturers of DOACs do not discourage clini-
cians from using this class of drugs in thrombo-
philic patients and in none of the VTE trials with 
DOACs was severe thrombophilia an exclusion 
criterion. It  has been postulated that “While it is 
possible the DOACs may be a  viable option for 
VTE treatment in patients with weaker underlying 
thrombophilias (e.g., heterozygous FVL), caution 
or avoidance, especially in highly pro-thrombotic 
states such as APS or heparin-induced thrombo-
cytopenia, is suggested until further evidence be-
comes available” [75]. Based on the current litera-
ture and our experience, we postulate using DOACs 
in thrombophilic patients initiating anticoagulant 
therapy and in those who prefer such a therapy or 
have unstable therapy with VKA. While perform-
ing a diagnostic evaluation for thrombophilia with 
the use of coagulation tests in patients receiving 
DOACs, at least 24 h  interval between the drug’s 
intake and blood collection should be confirmed, 
especially at the LA testing, which may require the 
interruption of the administration of DOACs for 
a period of 2–3 days. Such a procedure should be 
performed not earlier than after 3–6 months after 
the VTE event. The measurement of DOACs lev-
els in the samples tested may help interpret the re-
sults. Taken together, growing evidence indicates 
that DOACs are a  valuable and promising thera-
peutic option in the therapy of acute VTE as well 
as in secondary prevention of thrombotic events 
in individuals suffering from APS or inherited 
thrombophilic disorders. It  should be highlight-
ed that successful and safe treatment in this high-
risk population with DOACs requires good com-
pliance and adherence.
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